We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Waters and Tecan Sign Agreement for Clinical Assay Platform

By LabMedica International staff writers
Posted on 25 Jan 2012
Waters Corporation (Milford, MA, USA) and Tecan Group (Männedorf, Switzerland) entered into an agreement to combine Tecan’s Freedom EVO liquid handling platform with Waters Acquity TQD liquid chromatograph/mass spectrometer (LC/MS/MS) to automate sample preparation. More...
This will enable better, more efficient, and higher throughput clinical LC/MS assays.

Waters will combine the technologies from both companies into a single, fully supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve profitability, and reduce overall assay costs.

The firms announced the agreement at the annual meeting of the Association for Mass Spectrometry Applications to the Clinical Lab (MSACL) held on January 14-18, 2012, in San Diego (CA, USA).

"The multistep process of preparing samples for LC/MS/MS analyses remains a significant bottleneck and an opportunity for improvement in many laboratories. If there is one thing laboratory managers consistently ask for, it’s better, more automated sample preparation and analysis,” said Pat Martell, clinical marketing director, Waters Division. “Combining sample preparation and analysis in a single unified platform facilitates the entire assay process and streamlines analyses significantly. By lowering assay costs and bringing a greater consistency to test results, laboratories can offer clients a higher level of service and responsiveness."

Tecan is a global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production, and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories.

Waters innovations and laboratory solutions deliver better accuracy and precision for assays. The company is committed to helping laboratories deliver quality results with new levels of sample throughput, shortened turnaround times, and increases in sensitivity, specificity, and flexibility.

Related Links:
Waters Corporation
Tecan Group
The Association for Mass Spectrometry Applications to the Clinical Lab


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.